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The deduced amino acid sequences of CALLA, a cell surface marker of human acute lymphocytic leukemia, and human 
enkephalinase (neutral endopeptidase, EC 3.4.24.11) were recently reported to be almost identical. We show that mem- 
branes of CALLA+ cells of the REH lymphoblastic cell line as well as blast cells derived from the blood or bone marrow 
of patients with acute lymphocytic leukemia display high enkephalinase activity. This activity was abrogated by several 
enkephalinase inhibitors at concentrations closely similar to those required to inhibit pure human enkephalinase. How- 
ever, these compounds did not significantly modify the rate of REH cell proliferation in vitro. Hence, the functional 
role, if any, of the high peptidase activity in lymphoblastic cells remains to be established. 
Common acute lymphocytic leukemia antigen; Enkephalinase; Neutral endopeptidase; (REH cell line, Pre-B leukemic cell) 
1. INTRODUCTION 
Enkephalinase (EC 3.4.24.11, neutral endopep- 
tidase) is a 90 kDa membrane metallopeptidase in- 
itially characterized in brain [l] where its role in 
the inactivation of endogenous enkephalins has 
been established [2,3]. However, the enzyme has 
subsequently been found in many other tissues, 
particularly in kidney where a high activity is pre- 
sent [4], and has been shown [5-71 to be identical 
with a peptidase identified earlier by using the B- 
chain of insulin as substrate and designated 
‘neutral proteinase of kidney brush borders’ [8]. 
Following its purification, enkephalinase was 
shown to hydrolyse a variety of exogenous 
neuronal or hormonal peptides besides 
enkephalins, although its participation in the inac- 
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tivation of these other peptides in vivo largely re- 
mains to be established [9]. Recently, the cDNA 
sequences corresponding to the rat [lo], rabbit [ 1 l] 
and human enzymes [12] were reported. 
The common acute lymphoblastic leukemia an- 
tigen (CALLA/CD 10) is a cell surface marker in 
human acute lymphocytic leukemia, being express- 
ed by pre-B-phenotype leukemic cells but not nor- 
mal peripheral blood mononuclear cells. However, 
CALLA was also identified in a variety of nonlym- 
phoid cells including in the kidney [ 13,141. It was 
characterized as an approx. 100 kDa glycoprotein 
for which no biological activity was shown. 
However, the recent cloning and sequencing of a 
cDNA encoding for CALLA showed the deduced 
amino acid sequence to be strongly homologous to 
those of rat and rabbit enkephalinase and almost 
identical to that of the human enzyme [15,16]. 
We show here that a CALLA+ cell line and lym- 
phoblastic cells from leukemic patients express 
high enkephalinase activity. However, inhibition 
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of the peptidase by various compounds does not 
apparently modify the rate of in vitro proliferation 
of cells from the CALLA+ REH line. 
2. MATERIALS AND METHODS 
2.1. Cells 
The cell line REH, originally derived from an acute lym- 
phoblastic leukemia [17], was purchased from the American 
Tissue Culture Collection (ATCC, CRL 8 86 REH). Cells were 
grown as suspension culture in RPMI-1640 medium sup- 
plemented with 10% heat-inactivated fetal calf serum (Serom- 
ed. Biochrom., Berlin), penicillin, and streptomycin at 37°C in 
a humidified atmosphere of 5% COZ. 
Mononuclear cells from heparinized peripheral blood or the 
bone marrow of two patients with acute lymphoblastic 
leukemia were obtained by centrifugation through a Ficoll- 
Hypaque (Sigma, St. Louis, MO) density gradient (d = 1.077, 
Table 1 
Enkephalinase activity of various cells 
Cells Enkephalinase activity 
(pmol/min per lo6 cells) 
REH line 
Blood mononuclear 
Bone marrow 
Blood mononuclear cells of 
healthv donors 
1986 + 9.5 
1362 ? 39 
929 * 20 
<20 
The enzyme activity was evaluated by the fluorometric assay 
using 25 CM Sue-Ala-Ala-Phe-AMC as substrate and defined as 
that inhibited by 10 PM thiorphan. Means + SE of values from 
3 experiments 
400 x g, 20 min). Cells (CALLA+) were then washed twice with 
10% (v/v) fetal calf serum. A cell suspension was prepared in 
0.9% NaCl, adjusted to 5 x 106/ml and stored at - 20°C until 
enzyme assays. Control mononuclear cells from healthy donors 
were prepared in the same way. In order to obtain non-adherent 
cells, i.e. lymphocytes, cells were seeded for 2 h at 37°C in 
tissue culture flasks (75 ml, Corning, USA) containing a 
humidified atmosphere (5% COz). Viable non-adherent cells 
were then collected, washed in 0.9% NaCI, resuspended in the 
same medium (5 x lo6 cells/ml) and stored at -30°C until 
assays. 
2.2. Determination of enkephalinase activity 
After thawing at room temperature, cells were homogenised 
in their suspension medium by sonication for 10 s. 
Homogenates were centrifuged (30000 x g, 20 min, 4’C) and 
both supernatant and pellet (resuspended in 50 mM Tris-HCl 
buffer, pH 7.5) used for enzyme assays. 
Enkephalinase activity was evaluated on 50~1 of membrane 
suspensions or supernatants, using either a fluorometric [18] or 
an isotopic assay 1191. 
Briefly, for the fluorometric assay, the fluorogenic substrate 
was succinyl-Ala-Ala-Phe-amidomethylcoumarin (Suc-Ala- 
Ala-Phe-AMC, 25 PM final concentration). After 10 min in- 
cubation at 37°C released Phe-AMC was quantitatively 
hydrolysed in the presence of excess aminopeptidase M and the 
fluorescence quantified (excitation 367 nm; emission, 440 nm). 
For the isotopic assay, 40 nM [3H](D-Ala2,Leus)enkephalin 
(CEA, Saclay) was the substrate. After incubation for 30 min 
in the presence of 1 /cM captopril, an angiotensin-converting en- 
zyme inhibitor, and 1OpM bestatin, an aminopeptidase in- 
hibitor, the hydrolysis product was isolated by polystyrene bead 
column chromatography and the radioactivity quantified by li- 
quid scintillation spectrometry. 
In both assays, blanks were obtained by parallel incubations 
in the presence of 0.1 pM thiorphan. 
Recombinant human enkephalinase [12] was a kind gift from 
Bernard Malfroy (Genentech, San Francisco, USA). 
Table 2 
Inhibition of enkephalinase activity of human recombinant enkephalinase and CALLA+ cells by 
various compounds 
Enzyme source ICSO values (nM) 
Fluorometric assay Isotopic assay 
Thiorphan Phosphoramidon Thiorphan Kelatorphan 
Recombinant h-enkephalinase 1.5 + 0.1 2.0 + 0.1 1.4 f 0.2 2.2 * 0.1 
REH cell line 1.7 f 0.2 2.3 f 0.4 0.7 Z+Z 0.1 1.8 + 0.2 
Mononuclear blood cells from 
a leukemic patient 2.2 f 0.3 2.5 + 0.3 ND ND 
Enzyme activities were evaluated either on I ng recombinant enzyme and lo5 cells using 25 PM 
Sue-Ala-Ala-Phe-AMC (fluorometric assay) or on 10 ng recombinant enzyme and 10’ cells using 
40 nM [3H](D-Ala2,Leus)enkephalin ( sotopic assay) as substrate. Maximal inhibition was 98 + 
2% with the various enzyme sources and inhibitors. Values are means k SE calculated by least- 
squares analysis of concentration-inhibition plots established using at least five concentrations of 
the inhibitors and triplicate assays 
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Table 3 
Daily cell counts of REH cells cultured in the presence or 
abfence of enkephalinase inhibitors (number of cells: x 10W5) 
Controls Phosphoramidon Kelatorphan 
(10 rtM) (10 rM) 
Day 1 1.99 * 0.14 1.90 + 0.21 1.80 + 0.23 
Day 2 2.83 + 0.22 2.95 f 0.16 2.99 t 0.49 
Day 3 4.65 + 0.50 4.57 * 0.37 4.54 k 0.56 
Cells (10’ per ml at day 0) were suspended either in RPMI-1640 
medium supplemented with 10% fetal calf serum or in the same 
medium containing 10 pM phosphoramidon or kelatorphan 
and were counted every day for 3 days. Means + SE of data 
from 3 experiments 
3. RESULTS 
3.1. Characterization of enkephalinase activity of 
CALLA’ cells 
Membranes of all CALLA+ cells tested, i.e. the 
REH cell line, the blood and bone marrow blast 
cells from two patients with established iagnosis 
of acute lymphoblastic leukemia hydrolysed effi- 
ciently Sue-Ala-Ala-Phe-AMC (table 1) and 
[3H](D-Ala2,Leu5)enkephalin. In contrast, the 
hydrolysing activity was undetectable in the solu- 
ble fraction of the same cells and very weak 
(~20 pmol/min per lo6 cells) in corresponding 
blood cells from five normal donors. The pep- 
tidase activity responsible for hydrolysis of either 
substrate by CALLA+ cells was almost completely 
(-98%) inhibited by thiorphan, phosphoramidon 
or kelatorphan with ICSO values closely similar to 
those found with pure (recombinant) human 
enkephalinase (table 2). The enkephalinase activity 
of cultured REH cells (expressed per lo6 cells) did 
not significantly differ between days 0 and 3 of 
culture and corresponded approximately to that of 
50 ng pure enkephalinase. 
3.2. Effects of enkephalinase inhibitors on REH 
cell proliferation in vitro 
When REH cells were cultured in the presence of 
10 ,uM phosphoramidon, kelatorphan (table 3) or 
thiorphan (not shown), their proliferation, assess- 
ed by daily cell counts, did not significantly differ 
from that of cells cultured in their absence. 
4. DISCUSSION 
The present study indicates that CALLA+ lym- 
phoblastic cells derived from either the cell line 
REH or the circulant blood and bone marrow of 
leukemic patients express strong enkephalinase ac- 
tivity. The latter was characterized not only by the 
hydrolysis of typical substrates of the peptidase 
but also by the inhibitory potency of various com- 
pounds, i.e. thiorphan [20], phosphoramidon [8] 
and kelatorphan [21,22], which was closely similar 
to that found on recombinant human 
enkephalinase. These results could be expected 
from the virtual identity of the sequences of the 
human enzyme [12] and the CALLA antigen 
[15,16] but indicate, in addition, that the post- 
translational modifications of the protein in lym- 
phoblastic cells are adequate to provide it with po- 
tent peptidase activity. In particular, since the 
peptidase requires a tightly bound zinc atom to ex- 
press enzyme activity [23,24] this suggests that the 
level of Zn2+ in the cells (or culture media) was suf- 
ficient for the biosynthesis of a fully active 
enzyme. 
While this work was in progress, Shipp et al. [25] 
recently reported that a CALLA- murine myeloma 
cell line when transfected with CALLA cDNA ex- 
hibited potent enkephalinase activity, also in- 
dicating that expression of the antigen was 
associated with the typical peptidase activity. 
The role, if any, of the peptidase in prolifera- 
tion, differentiation or functions of lymphocytes is 
still a matter of conjecture. The present study in- 
dicates that its inhibition did not result in any 
significant change in the rate of in vitro prolifera- 
tion of a lymphoblastic cell line but does not ex- 
clude the possibility that the enzyme plays a critical 
role during lymphocyte differentiation. Our obser- 
vation that normal mature lymphocytes do not 
display measurable enkephalinase activity is con- 
sistent with previous observations showing that 
CALLA is only expressed by early normal lym- 
phoid progenitors [26-281. This may suggest hat 
the membrane-bound peptidase may act at a tran- 
sient stage of lymphoid cell differentiation by ac- 
tivating or inactivating a still unidentified 
extracellular peptide messenger. However, it is 
noteworthy that long-term treatments with 
enkephalinase inhibitors have thus far not disclos- 
ed any significant change in lymphoid tissues or 
blood lymphocyte counts in several animal species 
(Coquet, B. and Chipkin, R., personal com- 
munications). 
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